Asthma and COPD Drugs Market Size, Demand and Trends Analysis 2035
According to forecasts, the global asthma and COPD drugs market will grow to USD 70.27 billion by 2035, with an expected CAGR of 5.01%. In 2024, King's College London showed that benralizumab can reduce hospitalizations in severe asthma and treat asthma and COPD. Boehringer Ingelheim launched a $35/month inhaler program for uninsured or high-copay patients. AstraZeneca's AJAX and MIRANDA trials recruited participants in Europe.
Last Updated : 24 July 2026
Category: Therapeutic Area
Insight Code: 5011
Format: PDF / PPT / Excel